Managing type 2 diabetes during COVID-19

Managing type 2 diabetes during COVID-19

Boehringer Ingelheim - one of the world's leading pharmaceutical companies - held a regional media webinar titled 'Managing Type 2 Diabetes during COVID-19' with the participation of leading healthcare professionals who provided the latest updates on type 2 diabetes (T2D) management during the pandemic. The regional media event formed part of the 'Regional Interchange on Diabetes' (e-RID) internationally-accredited digital program, organized by Boehringer Ingelheim, targeting more than 5,000 international and regional healthcare professionals in the Middle East, Turkey and Africa region. By hosting prominent international experts from the USA, Canada and UK, the scientific program aims at exchanging experiences and practices in managing type 2 diabetes and its complications during COVID-19.



Thirty-nine million people are currently living with diabetes in the Middle East and North Africa, and it is estimated that by 2045, around 82 million people will have the condition, according to the International Diabetes Federation[2]. With diabetes being reported as a risk factor for the severity of COVID-19[3], patients are being encouraged to take precautions to avoid contracting the virus, such as washing hands thoroughly and regularly, cleaning and disinfecting objects and surfaces that are touched frequently, and avoiding contact with anyone showing symptoms of respiratory illness, such